Q3 Trade PfizerQ3 results for Pfizer were solid, with adjusted earnings and revenue surpassing expectations. The current drop in share price seems excessive and may be driven by liquidity concerns rather than underlying performance issues. The significant decline in expected sales for COVID products is concerning,